Search

The clinical trial NCT06650124 aims to compare the effectiveness of azathioprine (AZA) versus mycophenolate mofetil (MMF) in inducing remission in treatment-naive patients with autoimmune hepatitis (AIH). The study will assess whether MMF combined with prednisolone leads to higher remission rates compared to AZA with prednisolone after 24 weeks and if MMF is associated with fewer adverse events. Primary outcomes include the normalization of liver enzymes and IgG levels at 24 weeks, with secondary outcomes focusing on safety, treatment adherence, quality of life, and liver fibrosis reversal. Participants will receive either MMF or AZA alongside prednisolone and be monitored regularly to track remission and adverse events. [Extracted from the article]

A study conducted in Taipei, Taiwan, focused on the overlap between systemic lupus erythematosus (SLE) and autoimmune hepatitis (AIH) in hospitalized SLE patients. The research identified 5 cases of SLE-AIH overlap, with distinct therapeutic modalities and differential diagnosis between SLE-AIH overlap and lupus hepatitis (LH). Treatment with corticosteroids/azathioprine normalized liver function in LH cases, while refractory cases received B-cell depletion therapy or liver transplantation. The study provides valuable insights into the management of overlapping autoimmune conditions in SLE patients. [Extracted from the article]

The article discusses a case study of a 14-year-old girl with chronic active Epstein-Barr virus (EBV) infection, initially misdiagnosed as autoimmune hepatitis (AIH) due to similar symptoms. Despite treatment with steroids, the girl's condition worsened, leading to a diagnosis of CAEBV based on laboratory tests and biopsies. The researchers suggest considering CAEBV in cases of AIH or when AIH treatment is ineffective. The study highlights the complexity of diagnosing and treating chronic EBV infections in pediatric patients. [Extracted from the article]

A recent study conducted at Emek Medical Center in Afula, Israel, found that patients with autoimmune hepatitis (AIH) have a significantly higher risk of developing non-Hodgkin lymphoma (NHL) compared to the general population. The study, which included approximately 2.7 million adults over two decades, focused on AIH patients treated with immunosuppressive drugs such as azathioprine, 6-mercaptopurine, or mycophenolate mofetil. The research revealed that NHL incidence was notably higher in AIH patients, particularly affecting those over 45 years of age and detected within the first seven years following the AIH diagnosis. [Extracted from the article]

A recent study conducted at Cincinnati Children's Hospital Medical Center explored the association between MR elastography liver stiffness and histologic liver fibrosis in children and young adults with autoimmune liver disease. The research found a strong positive correlation between MRE liver stiffness and Metavir fibrosis stage, suggesting that MRE could be a valuable tool for noninvasive monitoring of liver fibrosis in this population. The study included 46 patients with autoimmune liver disease, and the findings support the potential clinical impact of using MRE for assessing liver fibrosis severity in pediatric patients. [Extracted from the article]

A study conducted at the University of Florence in Italy examined pediatric-onset autoimmune liver diseases, specifically autoimmune hepatitis, autoimmune sclerosing cholangitis, and primary sclerosing cholangitis. The research found that these conditions tend to manifest at progressively older ages and that elevated gamma-glutamyltranspeptidase levels combined with a high alkaline phosphatase/aspartate aminotransferase ratio can predict the diagnosis of sclerosing cholangitis. The study also noted that one-third of patients experienced liver-related adverse events, indicating the progressive nature of pediatric-onset autoimmune liver diseases. [Extracted from the article]

A randomized controlled clinical study is being conducted to evaluate the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma. The study will also assess the effectiveness and safety of low-dose radiotherapy versus standard-dose radiotherapy in neoadjuvant regimens that include benmelstobart with concurrent radiochemotherapy. This research aims to provide additional treatment options for patients with esophageal squamous cell carcinoma. [Extracted from the article]

A patent application titled "Systems And Methods For Treating Disease Through Peripheral Nerve Stimulation" was published online by inventors from San Francisco and San Mateo, California. The application focuses on treating inflammatory diseases, autoimmune diseases, and gastrointestinal conditions through neuromodulation, specifically targeting inflammatory bowel diseases like Crohn's disease, ulcerative colitis, and microscopic colitis. The method involves transcutaneous stimulation of peripheral nerves to modulate autonomic nervous system activity and reduce inflammation, offering potential new therapies for various medical conditions. [Extracted from the article]

A study conducted at Zhejiang University in the People's Republic of China focused on autoimmune hepatitis, a chronic liver disease caused by autoimmune reactions. The research highlighted the importance of developing novel therapeutic approaches for patients who do not respond well to standard treatments. The study reviewed recent advancements in the treatment of autoimmune hepatitis both domestically and internationally, emphasizing the need for ongoing research in this field. [Extracted from the article]

A recent study from the Institute for Experimental Immunology has introduced F-actin as a new marker antigen for primary sclerosing cholangitis, a liver disease. The research focused on developing a multiparametric immunoassay profile to detect autoantibodies associated with autoimmune hepatitis and primary biliary cholangitis. The addition of F-actin to the immunoassay profile is seen as a significant advancement in diagnosing liver diseases accurately. [Extracted from the article]

A recent study conducted by researchers at Southeast University in Nanjing, China, explored the use of liver biopsy for diagnosing unexplained portal hypertension. The study analyzed data from 188 patients with unexplained portal hypertension who underwent liver biopsy. The results showed that liver biopsy was valuable for determining the cause of portal hypertension, with cirrhosis being the most common cause. The study also highlighted the importance of considering porto-sinusoidal vascular disease as a potential cause of portal hypertension. The researchers concluded that while clinical features can provide some insight, pathological examination is essential for accurate diagnosis and assessment of disease progression. [Extracted from the article]

A study conducted by researchers from Cedars Sinai Medical Center in Los Angeles, California, compared waitlist and post-liver transplantation outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and autoimmune hepatitis (AIH) to those with MASLD alone and AIH alone. The study found that patients with MASLD/AIH had higher rates of encephalopathy and ascites, as well as higher Model for End-Stage Liver Disease (MELD) scores. They also had a higher incidence of liver transplantation and lower risk of waitlist removal compared to patients with MASLD alone. However, long-term post-transplantation outcomes did not significantly differ between the groups. The researchers suggest that further studies are needed to validate these findings. [Extracted from the article]

A recent study conducted at Washington University in St. Louis examined the impact of fibro-inflammatory activity on the biochemical remission of autoimmune hepatitis (AIH) patients. The researchers analyzed the diagnostic liver biopsy slides of 34 pediatric and 39 adult AIH patients and found that advanced fibrosis was present in 45.2% of cases. Patients with advanced fibrosis had higher levels of IgG and lower rates of biochemical remission at 6 months and 1 year post-diagnosis. The study suggests that advanced fibrosis is associated with more severe disease activity and poorer treatment outcomes in AIH patients. [Extracted from the article]

A recent study published in the journal Gastroenterology, Hepatology and Endoscopy Practice discusses the connection between autoimmune hepatitis and acute febrile illness. The researchers highlight that acute liver injury is a common clinical scenario faced by clinicians, and while hepatotropic viruses are the most common cause, other infectious agents like dengue, malaria, enteric fever, and leptospirosis can also lead to hepatic injury. The study reports a case of acute liver injury where the diagnosis was uncertain, as it could have been either leptospirosis or autoimmune hepatitis. The findings suggest that infections can trigger autoimmunity and complicate the diagnosis of autoimmune hepatitis. [Extracted from the article]

A recent study conducted by researchers at Indiana University School of Medicine has found that patients with autoimmune hepatitis (AIH) experience a high burden of unmet health-related needs, particularly those with low socioeconomic status (SES). The study surveyed 433 participants, the majority of whom identified as women, and found that over 70% reported at least one moderate-high need in various health-related domains. Patients with low SES were more likely to report unmet needs in areas such as adequate information about side effects, opportunities to speak with others with AIH, and being taken seriously by medical providers. The study highlights the importance of addressing the specific needs of AIH patients, particularly those from disadvantaged backgrounds. [Extracted from the article]

A recent report from researchers at Ross University School of Medicine focuses on autoimmune hepatitis, an inflammatory liver disease that primarily affects infants and adolescents. The case study discusses a 16-year-old male with a history of congenital ichthyosis who was diagnosed with autoimmune hepatitis and inflammatory bowel disease. The study highlights the challenges of diagnosing autoimmune hepatitis due to its similarities with other liver diseases. The prognosis for the patient appears to be positive. [Extracted from the article]

A new report discusses research on autoimmune hepatitis, a condition in which the immune system mistakenly attacks the liver. The study analyzed the efficacy and safety of infliximab, a drug used in the treatment of autoimmune diseases, in patients with autoimmune hepatitis. The researchers found that infliximab was effective in achieving complete biochemical response in a majority of patients, particularly those who had failed standard or alternative therapies. The study suggests that infliximab may be a safe and effective rescue therapy for autoimmune hepatitis. [Extracted from the article]

A recent study conducted at Riga East University Hospital in Latvia examined the clinical features, treatment challenges, and outcomes of patients with autoimmune hepatitis over a five-year period. Autoimmune hepatitis is an inflammatory liver disease of unknown cause that can lead to cirrhosis and liver failure. The study found that the diagnostic criteria for autoimmune hepatitis were generally consistent with accepted principles, but the duration of therapy did not always align with guidelines. The researchers emphasized the importance of individualized treatment regimens and balancing treatment goals with personal choices. [Extracted from the article]

A study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explores the role of B and T cells in the development of autoimmune hepatitis (AIH). AIH is a severe liver disease characterized by hypergammaglobulinemia, the presence of autoantibodies, and interface hepatitis. The study found that B cells play an active role in liver damage by presenting autoantigens to T cells, while Treg impairment contributes to the progression of liver damage. The research also discusses potential immunotherapeutic strategies to limit inflammation and restore tolerance to liver autoantigens. [Extracted from the article]

Researchers from An-Najah National University have published a case report on a rare neoplasm called post-transplantation primary central nervous system lymphoma (PT-PCNSL) that occurs in immunocompromised patients. The report describes the case of a 64-year-old woman who had received a liver transplant for autoimmune hepatitis and presented with neurological symptoms. Brain MRI revealed multiple ring-enhancing lesions, and a brain biopsy confirmed the diagnosis of PT-PCNSL. This is the first reported instance of isolated CNS lymphoma in a liver transplant recipient with autoimmune hepatitis, successfully treated with a rituximab-methotrexate regimen. The timely recognition of PT-PCNSL is crucial for appropriate management and improved outcomes. [Extracted from the article]

A study conducted by researchers at Cliniques Universitaires Saint-Luc in Brussels, Belgium, evaluated the effectiveness of a ten-antigen immunodot test in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). The study analyzed serum samples from 111 patients and found that the immunodot panel accurately confirmed positive results from other diagnostic tests, except for two samples. The immunodot test also identified additional autoantibodies in samples initially negative by other tests. The researchers concluded that the immunodot technique is a quick, sensitive, and specific method that could improve diagnostic efficiency and accuracy in clinical practice for autoimmune liver diseases. [Extracted from the article]

The patent application by inventor LAI, Laijun, filed on March 4, 2024, discusses methods for treating cancer and autoimmune diseases. It describes the use of antibodies that selectively bind to specific proteins to treat cancer, as well as the use of IgV domains from certain proteins or expression vectors to treat autoimmune disorders. The application provides detailed information on the amino acid sequences of the antibodies and their potential therapeutic applications. It also includes information on isolated antibodies, nucleic acids encoding these antibodies, fusion molecules, and pharmaceutical compositions for treating cancer and autoimmune disorders. [Extracted from the article]

A case report from Virginia Commonwealth University describes a successful simultaneous liver and kidney transplantation (SLKT) in a highly sensitized O recipient with organs from an A2 donor. The recipient was a 59-year-old woman with chronic kidney disease and liver failure. The study found that SLKT is feasible in patients with both donor-specific HLA antibodies and high anti-A2 titers. This research provides valuable insights into the field of transplant medicine and kidney transplants. [Extracted from the article]

A report from the Children's Memorial Health Institute in Warsaw, Poland discusses the findings of a study on autoimmune hepatitis in pediatric patients. The study specifically focuses on classical autoimmune hepatitis and IgG4-associated autoimmune hepatitis. The researchers conducted a retrospective analysis of 23 children diagnosed with autoimmune hepatitis and compared them based on the presence of IgG4-positive plasma cells in liver biopsies. The study concludes that the presence of the IgG4 component is clinically insignificant and recommends the use of conventional immunosuppressive treatment for IgG4-associated autoimmune hepatitis. [Extracted from the article]

Researchers from Ghent University in Belgium have conducted a study to validate the International Autoimmune Hepatitis Group's (IAIHG) consensus criteria for treatment response in autoimmune hepatitis (AIH). The study involved a multicentric cohort of 200 AIH patients and found that achieving complete biochemical response (CBR) according to the IAIHG criteria was associated with superior liver-related and overall survival. The researchers concluded that the IAIHG criteria can be used as intermediate endpoints in future studies on non-corticosteroid treatments for AIH. This information is valuable for patients and healthcare professionals seeking to understand treatment response and improve outcomes in AIH. [Extracted from the article]

A study conducted by researchers from Iwate Medical University in Morioka, Japan, highlights the case of a 37-year-old woman with severe acute liver injury caused by autoimmune hepatitis. Despite treatment with prednisolone, her prothrombin time (PT) did not return to normal levels. Further examination revealed that she had low factor VII activity, indicating a diagnosis of factor VII deficiency. The researchers suggest that altered coagulopathy should be considered in cases of liver injury with abnormal PT. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Warsaw in Poland has found that previous infection with the Hepatitis E virus (HEV) is associated with increased liver stiffness in patients with autoimmune hepatitis (AIH). AIH is a chronic liver disease that often requires lifelong immunosuppression. The study involved 374 adult patients with AIH, and it found that 15% of them were positive for anti-HEV antibodies. These patients had higher liver stiffness measurements, indicating more advanced liver fibrosis. However, the overall prevalence of anti-HEV antibodies in AIH patients was lower than in the general population of Polish blood donors. [Extracted from the article]

A recent study conducted at a Teaching Hospital has provided new insights into cutaneous lupus erythematosus, a condition where autoimmune hepatitis overlaps with subacute cutaneous lupus erythematosus. The study focused on a case of a 35-year-old male who had been diagnosed with autoimmune hepatitis five years prior and later developed symptoms of systemic lupus erythematosus. The patient was successfully managed with immunosuppressive medication. This research sheds light on the rare entity of AIH subacute cutaneous lupus erythematosus overlap syndrome. [Extracted from the article]

A recent study conducted by researchers at Sao Paulo State University (UNESP) in Brazil explores the risks and benefits of using anti-tumor necrosis factor (TNF) therapy for ulcerative colitis (UC) in a patient with autoimmune hepatitis-related cirrhosis. The study focuses on a rare case of a 28-year-old female patient who had liver cirrhosis due to autoimmune hepatitis (AIH) and UC that was unresponsive to conventional treatment. The patient was treated with infliximab, a TNF inhibitor, and initially showed a positive response. However, after eight months of therapy, the patient developed pneumonia with complications and died. The study highlights the importance of carefully evaluating the best treatment options for patients with overlapping IBD and AIH, considering the potential side effects, particularly infections, especially in patients with cirrhosis. [Extracted from the article]

Researchers from the First Affiliated Hospital of Wenzhou Medical University have conducted a study on experimental autoimmune hepatitis (AIH) and its potential treatment options. The study focused on the role of fibroblast growth factor 4 (FGF4) in regulating M1 macrophages and reducing liver inflammation in AIH. The researchers found that FGF4 treatment activated the PI3K-AKT signaling pathway in macrophages, leading to a reduction in M1 macrophages and hepatic inflammation. This study suggests that FGF4 may be a novel target for treating inflammation in patients with AIH. [Extracted from the article]

A case study conducted by researchers at Manchester University NHS Foundation Trust in the United Kingdom has reported a case of autoimmune hepatitis associated with the use of the PCSK9 inhibitor alirocumab. The study describes the case of a 61-year-old woman who developed hepatitis after being prescribed atorvastatin for familial hypercholesterolemia. After her liver function tests normalized, she was prescribed alirocumab, which also led to hepatitis. A liver biopsy confirmed that she had autoimmune hepatitis with presumed drug injury, making this the first reported case of autoimmune hepatitis associated with alirocumab. [Extracted from the article]

A recent study conducted by researchers at Eskisehir Osmangazi University focused on the relationship between systemic lupus erythematosus (SLE) and hepatic hemangiomas. SLE is an autoimmune disease that affects multiple organs, including the liver. The study reported a case of a 36-year-old woman with SLE who was diagnosed with multiple hepatic hemangiomas. The researchers highlighted the potential increased incidence of hepatic hemangiomas in individuals with SLE. This study provides valuable insights into the connection between SLE and hepatic hemangiomas, shedding light on a topic that has not been extensively studied. [Extracted from the article]

A recent study conducted at the University Medical Centre Hamburg-Eppendorf (UKE) in Germany explored the optimization of thiopurine therapy in autoimmune hepatitis (AIH). The researchers investigated whether patients could be stratified based on their response to thiopurine metabolites and examined the effects of azathioprine dosage increases and co-therapy with allopurinol on metabolite profiles and treatment response. The study found that maintaining complete biochemical remission (CBR) in AIH was associated with specific levels of thiopurine metabolites. For patients who did not achieve CBR despite dose increases, the addition of allopurinol alongside low-dose thiopurines was found to be an effective alternative. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Wenzhou Medical University has found that one-third of patients with autoimmune hepatitis (AIH) have cirrhosis at the time of diagnosis. The study aimed to explore the role of polymeric immunoglobulin receptor (pIgR) in regulating the secretion of regenerating islet-derived 3 beta (Reg3b) and the composition of gut microbiota in AIH. The researchers discovered that pIgR facilitates the upregulation of Reg3b through the STAT3 pathway, which plays a crucial role in maintaining the balance of intestinal microbiota in AIH. These findings provide new molecular targets for the diagnosis and treatment of AIH. [Extracted from the article]

A new report from Vilnius University in Lithuania discusses a rare case of bullous morphea associated with autoimmune hepatitis. Bullous morphea is a rare form of localized scleroderma characterized by the presence of sporadic and intermittent blisters on sclerodermatous skin. The exact mechanisms that lead to the development of this condition are largely unknown, making diagnosis and treatment challenging. The case report highlights the importance of considering overlapping autoimmune conditions and the potential efficacy of systemic corticosteroids in managing bullous morphea. Further research is needed to better understand the pathogenesis of this condition and develop more effective treatment options. [Extracted from the article]

A study conducted by the Department of Gastroenterology and Hepatology in Roeselare, Belgium, has found that a rare case of drug-induced liver injury was caused by a CYP2D6 gene polymorphism that led to dysfunction and accumulation of a potentially hepatotoxic metabolite of the drug Trazodone. The patient, a 46-year-old female with a history of type I diabetes, alopecia areata, and autoimmune hypothyroidism, experienced significant hepatocellular hepatitis. The researchers recommend targeted pharmacogenomic testing to minimize the risk of drug-induced liver injury. This research has been peer-reviewed and published in Acta Gastro Enterologica Belgica. [Extracted from the article]

A review conducted by researchers at Shiraz University of Medical Sciences in Iran discusses the potential of regulatory T-cell (Treg) infusion therapy in the treatment of autoimmune diseases and organ transplantation. The infusion of Tregs has shown promise in preventing autoimmune reactions and acute/chronic allograft rejection. The review highlights the efficacy of Treg therapy in various autoimmune diseases and allograft transplantation, but also acknowledges the technical challenges and limitations of this approach. The research provides an up-to-date overview of Treg infusion-based treatments and their strengths and limitations. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of autoimmune hepatitis in mice with a deficiency in DNase II. The study found that these mice exhibited features similar to human autoimmune hepatitis, including liver inflammation and fibrosis. The infiltration of various immune cells, such as T cells and monocytes, was observed, and the expression of TLR9 by bone marrow-derived cells was found to be necessary for the development of autoimmune hepatitis. The study also highlighted the role of IFNγ signaling in the recruitment and activation of these immune cells. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the University of Pennsylvania examined the factors associated with treatment patterns in US patients with autoimmune hepatitis (AIH). The study found that while long-term corticosteroid avoidance is a common goal in managing AIH, prolonged immunosuppression is often necessary to prevent disease progression. The research identified patient and provider factors that influenced treatment choices, such as ethnicity, cirrhosis, osteoporosis, and provider experience. The study also revealed that long-term prednisone therapy is still prevalent, particularly among patients with comorbidities that may be aggravated by corticosteroids. [Extracted from the article]